20/20 Biolabs Inc. (AIDX) Stock Overview
Explore 20/20 Biolabs Inc.’s financial performance, market position, analyst ratings, and future outlook.
20/20 Biolabs Inc. (AIDX)
Key Financials
Key Financials
Market Cap
2.8M
P/E Ratio
-0.85
EPS (TTM)
$-0.53
ROE
0.79%
AIDX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of 20/20 Biolabs Inc. (NASDAQ: AIDX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, 20/20 Biolabs Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of AIDX on the NASDAQ shows an RSI of 32.28, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.
Key metrics behind 20/20 Biolabs Inc.'s NASDAQ-traded stock include a P/E ratio of -0.85 and a market capitalization of 2.8M. Combined with our AI analysis, these give both institutional and retail investors a clear view of AIDX on the NASDAQ.